Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy

Figure 4

Anti-PD-L1 antibody combined with radiotherapy represses BC cell growth and promotes apoptosis in vivo. miR-21^+/+ mice were either treated or not treated with radiotherapy or radiotherapy + anti-PD-L1 antibody. (a) Tumor volume curve of miR-21^+/+ mice following different treatment protocols. (b) Tumor weight of miR-21^+/+ mice following different treatment protocols. (c) The number of PD-L1 positive cells in tumor tissues of miR-21^+/+ mice following different treatment protocols, detected by immunofluorescence staining. (d) The positive rate of Ki67 protein expression in tumor tissues of miR-21^+/+ mice following different treatment protocols, detected by immunohistochemistry (10 mice in each group, 3 sections for each mouse). (e) Cell apoptosis in tumor tissues of miR-21^+/+ mice following different treatment protocols, measured using TUNEL staining. (f) Protein levels of apoptosis-related factors in tumor tissues of miR-21^+/+ mice following different treatment protocols, determined by Western blot analysis. , compared with miR-21^+/+ mice without treatment; ^#, compared with miR-21^+/+ mice treated with radiotherapy or anti-PD-L1 antibody. Each sample was evaluated three times independently. Data () from two groups were compared using independent sample -test. There were 10 mice in each group.

(a)

(b)

(c)

(d)

(e)

(f)